FluBlok, a recombinant influenza vaccine

V. C. Huber, Jonathan Mccullers

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Protein Sciences Corp and UMN Pharma Inc are developing FluBlok, an injectable trivalent influenza vaccine formulation composed of recombinant influenza hemagglutinin (HA) proteins that match the HA from the three influenza isolates that currently circulate in humans (H1N1, H3N2 and B), for the potential prevention of influenza virus infection. Phase III clinical trials to compare FluBlok and a licensed trivalent influenza vaccine for immunogenicity, safety and efficacy in preventing naturally occurring influenza are ongoing.

Original languageEnglish (US)
Pages (from-to)75-85
Number of pages11
JournalCurrent Opinion in Molecular Therapeutics
Volume10
Issue number1
StatePublished - Feb 1 2008

Fingerprint

Synthetic Vaccines
Influenza Vaccines
Human Influenza
Hemagglutinins
Phase III Clinical Trials
Virus Diseases
Orthomyxoviridae
Proteins
Safety
Injections
FluBlok

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Cite this

FluBlok, a recombinant influenza vaccine. / Huber, V. C.; Mccullers, Jonathan.

In: Current Opinion in Molecular Therapeutics, Vol. 10, No. 1, 01.02.2008, p. 75-85.

Research output: Contribution to journalReview article

@article{11650b26eff945aaa645815e845f516c,
title = "FluBlok, a recombinant influenza vaccine",
abstract = "Protein Sciences Corp and UMN Pharma Inc are developing FluBlok, an injectable trivalent influenza vaccine formulation composed of recombinant influenza hemagglutinin (HA) proteins that match the HA from the three influenza isolates that currently circulate in humans (H1N1, H3N2 and B), for the potential prevention of influenza virus infection. Phase III clinical trials to compare FluBlok and a licensed trivalent influenza vaccine for immunogenicity, safety and efficacy in preventing naturally occurring influenza are ongoing.",
author = "Huber, {V. C.} and Jonathan Mccullers",
year = "2008",
month = "2",
day = "1",
language = "English (US)",
volume = "10",
pages = "75--85",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "1",

}

TY - JOUR

T1 - FluBlok, a recombinant influenza vaccine

AU - Huber, V. C.

AU - Mccullers, Jonathan

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Protein Sciences Corp and UMN Pharma Inc are developing FluBlok, an injectable trivalent influenza vaccine formulation composed of recombinant influenza hemagglutinin (HA) proteins that match the HA from the three influenza isolates that currently circulate in humans (H1N1, H3N2 and B), for the potential prevention of influenza virus infection. Phase III clinical trials to compare FluBlok and a licensed trivalent influenza vaccine for immunogenicity, safety and efficacy in preventing naturally occurring influenza are ongoing.

AB - Protein Sciences Corp and UMN Pharma Inc are developing FluBlok, an injectable trivalent influenza vaccine formulation composed of recombinant influenza hemagglutinin (HA) proteins that match the HA from the three influenza isolates that currently circulate in humans (H1N1, H3N2 and B), for the potential prevention of influenza virus infection. Phase III clinical trials to compare FluBlok and a licensed trivalent influenza vaccine for immunogenicity, safety and efficacy in preventing naturally occurring influenza are ongoing.

UR - http://www.scopus.com/inward/record.url?scp=38649128503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649128503&partnerID=8YFLogxK

M3 - Review article

VL - 10

SP - 75

EP - 85

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 1

ER -